Abstract Library

#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barriuso J, Lamarca A, McNamara M, Manoharan P, Moghadam S,

Keywords: pNETs, WES, everolimus, sunitinib,

#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Manoharan P

Authors: Manoharan P, Navalkissoor S, Lamarca A, Calero J, Chan P,

Keywords: SomaKit, DOTATOC, GEP-NET,

#1486 Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1

Introduction: The role of minimally invasive pancreatic surgery for pancreatic neuroendocrine neoplasms (pNENs) in patients with multiple endocrine neoplasia type 1 (MEN1) is not well defined.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Albers M, Bollmann C, Manoharan J, Waldmann J,

Keywords: pancreatic neuroendocrine neoplasm, laparoscopic pancreatic resection, MEN1,

#1438 An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Manoharan J, L. Lopez C, Hackmann K, Albers M, Pehl A,

Keywords: MEN1, Deletion mutation, SI-NEN,

#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?

Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Manoharan J, Lopez C, Albers M, Bollmann C, Slater E,

Keywords: Screening, MEN1,